이상반응 보고

VAERS ID	2584589
성별	남성
나이
주 코드	FR
제약회사	PFIZER\BIONTECH
로트 번호
예방접종 횟수	4
접종일	2022-10-14
발병일	2022-10-15
상태	입원 사망

증상

이환 중 질병

지병

기타 의료

이전 예방접종

알레르기

임상 검사

증상 상세

visual disturbances; cough; weakness; MOG antibody-associated disease; therapy-refractory encephalitis; hiccups; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from Regulatory Authority.
Regulatory number: CH-SM-2023-10842 (RA).
A 50-year-old male patient received BNT162b2, BNT162b2 omi ba.
1 (COMIRNATY), on 14Oct2022 as dose 4 (booster), single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation.
The patient's relevant medical history and concomitant medications were not reported.
Vaccination history included: Comirnaty (dose 1), administration date: Jun2021, for COVID-19 immunisation; Comirnaty (dose 2, 3-4 weeks after 1st dose), for COVID-19 immunisation; Comirnaty (dose 3 (booster)), administration date: 2022, for COVID-19 immunisation.
The following information was reported: HICCUPS (non-serious) with onset 2022, outcome "unknown"; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (death) with onset 15Oct2022, outcome "fatal", described as "MOG antibody-associated disease"; COUGH (non-serious) with onset 15Oct2022, outcome "not recovered"; ENCEPHALITIS (death) with onset 15Oct2022, outcome "fatal", described as "therapy-refractory encephalitis"; ASTHENIA (non-serious) with onset 15Oct2022, outcome "not recovered", described as "weakness"; VISUAL IMPAIRMENT (hospitalization), 3 weeks after the suspect product(s) administration, outcome "unknown", described as "visual disturbances".
Clinical course details: The patient developed cough and weakness one day after the fourth vaccination, from which he did not recover.
The patient also developed hiccups over time.
After 3 weeks, there were additional visual disturbances, whereupon the patient presented to the doctor and was hospitalized.
In the further clarification, a Myelin oligodendrocyte glycoprotein antibody-associated disease was diagnosed.
In the course of the disease, the patient developed therapy-refractory encephalitis as part of the Myelin oligodendrocyte glycoprotein antibody-associated disease, after which he died on 08Dec2022.
The symptoms of the autoimmune disease first manifested themselves after the vaccination before which the patient had been completely healthy.
No other previous illnesses were known.
He also took no further long-term medication until the onset of the symptoms.
The hospital suspected that the vaccination could possibly be a trigger for the autoimmune disease.
The event "visual disturbances" required physician office visit.
The patient date of death was 08Dec2022.
Reported cause of death: "Myelin oligodendrocyte glycoprotein antibody-associated disease was diagnosed", "therapy-refractory encephalitis".
It was not reported if an autopsy was performed.
Causal relationship between the adverse event(s) Myelin oligodendrocyte glycoprotein antibody-associated disease and the administration of Comirnaty was assessed as Possible by the RA.
Follow-up attempts are completed.
No further information is expected.
; Reported Cause(s) of Death: Myelin oligodendrocyte glycoprotein antibody-associated disease was diagnosed; therapy-refractory encephalitis